• Consider a bearish position in Recursion Pharmaceuticals (RXRX) only if comfortable with high risk; the discussion flags uncertain pipeline value, substantial cash burn, and possible dilution as key concerns.
• Twist Bioscience (TWST) may offer growth exposure, but the speaker viewed its roughly $10 billion valuation as difficult to justify before stronger margins and profitability emerge.
• Liquidia (LQDA) received a bullish personal endorsement, but no price target, catalyst, or supporting thesis was provided, so further research is needed before acting.
• Avoid trading ASML on unverified claims about upcoming results; rely on public disclosures rather than potentially material nonpublic information.

Recursion Pharmaceuticals (RXRX)

• The speaker was strongly bearish and called RXRX “a good short,” arguing that its $2.4 billion market capitalization was difficult to justify given the drug pipeline and execution concerns.
• He questioned whether the company’s AI platform had produced a meaningful advantage. He described several drug targets as unpromising or already well explored, and said one pipeline drug was licensed from Takeda rather than discovered using AI.
• The speaker singled out REC-7735, a drug aimed at a specific PI3K-alpha mutation, as the pipeline’s most potentially interesting candidate. But he noted competing research and drugs in the area, and questioned whether RXRX could execute successfully.
• He cited annual cash burn of roughly $375 million to $400 million, about $500 million in cash, no revenue, and an increase in shares outstanding from roughly 300 million to 500 million. He contrasted his estimate of about a year of cash with the company’s stated runway through 2028.
• He also criticized the company’s past pipeline progress, saying some programs had been paused, dropped, or returned to partners. RXRX has received payments from Genentech and Sanofi, but he did not view those partnerships as enough to make the investment compelling.
• The company’s relationship with NVIDIA (NVDA) was mentioned, but the speaker dismissed it as insufficient evidence that RXRX’s drug-development approach is working.

Takeaways

• The discussion presents a high-risk bearish thesis centered on uncertain pipeline value, cash consumption, dilution, and doubts about the commercial usefulness of RXRX’s AI platform.
• REC-7735 was described as a possible exception, but the speaker still questioned its differentiation and RXRX’s ability to develop it.
• Investors evaluating this thesis could focus on pipeline updates, clinical results, cash runway, and share-count changes. The transcript’s assertions are the speaker’s opinions, not independently verified findings.

Twist Bioscience (TWST)

• The speaker described Twist as a tools and products business, not a drug company, and questioned whether it should be considered an AI-biology beneficiary.
• He cited revenue growth of roughly 20% to 46% in recent periods and saw potential for continued growth. He also said the business could have strategic value if biological tools become more important across fields.
• At the same time, he called the valuation—about a $10 billion market capitalization in his discussion—“outlandish” and “nuts.” He noted relatively low gross margins, substantial R&D and selling costs, and continued losses, with profitability in his projections not arriving until around 2028.
• He said some product areas, including synthetic genes, oligo pools, and DNA libraries, may be commoditized; antibody discovery had been sluggish. Next-generation sequencing tools appeared to be growing more strongly, though he questioned how much that business had to do with AI or drug discovery.
• His valuation scenario assumed exceptionally strong growth—including about 40% annual growth for several years—and limited expense growth. He acknowledged that this was an extremely optimistic scenario, though such growth could support substantial upside.

Takeaways

• The discussion is mixed: it recognizes growth and possible strategic value but argues the stock price may already assume an unusually successful future.
• A key investment question raised is whether growth—especially in sequencing-related products—can continue while margins improve and expenses are controlled.
• The optimistic growth scenario was explicitly described as highly rosy, not as a forecast or recommendation.

Liquidia (LQDA)

• The speaker said he was still invested in Liquidia and “really like[d] that opportunity,” expressing hope that it would “come back big.”
• The transcript provides no specific valuation, price target, catalyst, timeline, or detailed investment thesis for Liquidia.

Takeaways

• The comments indicate a bullish personal view, but offer too little supporting detail to assess the opportunity from the discussion alone.
• The speaker’s position and optimism should not be treated as a substitute for researching the company’s business, financials, and risks.

ASML (ASML)

• A viewer urged the speaker to short ASML. The speaker cautioned the viewer not to share potential insider information, particularly because the viewer claimed to work at the company.
• The speaker said he had heard that the quarter had gone very well and that ASML might report “blowout numbers.” He challenged the viewer’s claims but did not present this as a formal forecast or investment recommendation.

Takeaways

• The comments convey a near-term bullish impression based on unverified talk about quarterly performance, not a substantiated investment thesis.
• The speaker explicitly raised the risk of sharing or trading on material nonpublic information. Public investors should base decisions on publicly available information.

Ethereum (ETH)

• Ethereum was briefly mentioned with the phrase “ETH is out today.” No explanation, price view, or investment thesis followed.

Takeaways

• The transcript provides no actionable view on Ethereum’s outlook or whether the speaker is bullish or bearish.

Moderna (MRNA)

• Moderna was mentioned briefly, with the speaker saying there was “not much to look out for” in the context of the companies being discussed. No analysis or specific recommendation followed.

Takeaways

• The comment is too brief to establish a meaningful investment thesis or sentiment beyond a lack of discussion in that segment.